Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Aptar (NYSE:ATR) announced its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory's Phase II study of investigational INNA‑051, with first participants dosed on March 19, 2026. The study evaluates safety, tolerability and potential effectiveness of a once‑weekly nasal spray for adults at increased exposure risk.
The UDS system supplies single, precise dry powder doses, modular moisture protection via a 3‑Phase Activ‑Polymer™ container closure, and internal safeguards against premature actuation to support clinical administration and formulation stability.
Aptar (NYSE:ATR) named Gael Touya as President and CEO effective September 1, 2026, succeeding Stephan B. Tanda, who will advise through year‑end and retire from the Board by end of 2026. The announcement highlights Gael’s 30+ years at Aptar and ~82% Aptar Pharma topline growth since 2018.
Stephan’s tenure (2017–2025) saw adjusted EBITDA expand from ~19% to ~22%, adjusted EPS +67%, and capital returned to shareholders up ~100%.
Aptar (NYSE:ATR) announced its proprietary multidose intranasal delivery system is being used in LTR Pharma's Phase II study of SPONTAN®, an investigational intranasal spray for erectile dysfunction. Aptar teams Nanopharm and Noble support formulation, analytical testing, human factors and risk management to advance clinical and regulatory readiness.
The announcement notes first-patient dosing in the Phase II study and emphasizes Aptar Pharma's role providing dosing accuracy, stability data and usability validation to support development.
Aptar (NYSE: ATR) will present at two investor conferences in early 2026. Stephan Tanda, President and CEO, will speak at the Bank of America Securities 2026 Global Agriculture and Materials Conference on Feb 25, 2026 at 9:45 a.m. ET. Vanessa Kanu, EVP and CFO, will speak at the Raymond James 2026 Institutional Investors Conference on Mar 3, 2026 at 1:05 p.m. ET. A live audio webcast and presentation materials will be available in the Investors section of the company website.
AptarGroup (NYSE:ATR) reported fourth quarter 2025 results: reported sales $963M (+14% YoY), core sales +5%, fourth-quarter reported net income $74M (−26%) and reported EPS $1.13 (−24%). Adjusted EPS was $1.25 and adjusted EBITDA margin was 19.8% (down from 23.0%).
For full year 2025, reported sales were $3.78B (+5%), reported EPS $5.89 (+7%), cash flow from operations $570M, free cash flow $303M, and the Board approved a new $600M share repurchase authorization. Q1 2026 adjusted EPS guide: $1.13–$1.21.
Aptar (NYSE: ATR) announced a $0.48 per share quarterly cash dividend, payable on February 25, 2026 to stockholders of record as of February 4, 2026. The company will host a conference call on February 6, 2026 at 8:00 a.m. Central Time to discuss fourth-quarter and full-year 2025 results, with a live webcast and limited-time replay available on the investor website.
The Board also set the 2026 Annual Meeting of Stockholders for a virtual session on May 6, 2026 at 9:00 a.m. Central Time, with a record date for voting of March 13, 2026. Additional meeting access details will be provided closer to the event.
Aptar (NYSE: ATR) achieved an “A” score on the CDP Climate Change Assessment for the second consecutive year, placing the company among the top 4% of nearly 20,000 scored organizations based on its 2025 disclosure. Aptar reported actions to cut emissions, mitigate climate risks and advance a low-carbon economy, supported by SBTi-validated Scope 1 and Scope 2 targets aligned to 1.5°C by 2030, a Scope 3 target, renewable electricity goals, and Power Purchase Agreements in Europe and the US. The company also improved TCFD disclosures and received ISO 14046 certification, reflecting increased renewable purchases and GHG reductions across scopes.
Aptar (NYSE: ATR) announced that its nasal delivery devices LuerVax and Spray Divider are being used in CastleVax’s Phase II trial of CVAX-01, an intranasal COVID-19 vaccine candidate.
The trial will enroll about 200 U.S. adults, including high-risk and 65+ participants, and follow them for six months to compare safety, tolerability and systemic and mucosal immune responses versus an FDA-approved injectable mRNA vaccine. Aptar cites its regulatory and technical support, device/formulation expertise, and Pharma Services capabilities to support development and accelerate time-to-market.
Aptar (NYSE: ATR) outlined its eye care portfolio highlighting the new Beat the Blink™ delivery system designed to improve dosing precision by delivering horizontal drops and protecting preservative-free formulas with a tip seal. Beat the Blink is in an exclusive partnership with Bausch and Lomb and commercial availability is estimated after development and industrialization in 24–36 months. Aptar also described its Ophthalmic Squeeze Dispenser (OSD) with Tip-Seal microbial testing, APF preservative-free pumps and the recyclable APF Futurity metal-free nasal system, plus digital healthcare solutions for patient monitoring and eye care support.
Aptar (NYSE: ATR) announced its 2026 quarterly conference call schedule with dates and times for earnings-related calls and accompanying press release timing.
Press release dates (after NYSE close) and conference calls (all at 8:00 a.m. CT):
- 4Q & Annual 2025: Press release Feb 5, 2026 — Call Feb 6, 2026
- 1Q 2026: Press release Apr 30, 2026 — Call May 1, 2026
- 2Q 2026: Press release Jul 30, 2026 — Call Jul 31, 2026
- 3Q 2026: Press release Oct 29, 2026 — Call Oct 30, 2026
Calls are ~one hour, held in Central time, available live via webcast at the company investor website with replay access on the Investors page. Any updates will be announced in later releases.